SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly net profit, along with strong revenue and delivery guidance, which has ignited bullish sentiment for a significant revaluation and potential short squeeze. Community discussion centers on overcoming key resistance levels as the company demonstrates improved margins and competitive positioning in the EV market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending due to persistent speculation and community chatter about its potential integration as an incentive or payment option within Elon Musk's "X money" platform, with some users reporting internal beta access. This buzz is generating significant discussion regarding a possible meme coin resurgence and a major price rally, though skepticism about a typical "pump and dump" cycle also remains prevalent among traders.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is a hot topic as its community celebrates a significant anniversary, underscoring its resilience and battle-tested status while discussing the impact of its newly active token incinerator, continuous $SOL rewards, and a new high-multiplier liquidity pool.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is actively discussed amid reports of wiring flaws impacting some 737 MAX production, which the company states will cause short-term delays but not affect year-end delivery goals. This quality concern sparks community debate between those worried about ongoing issues and others who view it as an overreaction, highlighting Boeing's robust order backlog, recent delivery figures, and potential for new large contracts.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a substantial Q4 2025 earnings beat, propelled by accelerating MIPLYFFA sales that highlight its transition to a profitable commercial-stage company. The community is buzzing about this fundamental shift, anticipating analyst upgrades, further momentum from pending EU approval, and a potential short squeeze.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech ($CITR) is experiencing a surge of attention due to its presentation at a virtual investor conference, with community discussion highlighting its extremely low float and unique fire-retardant wood technology as key drivers for potential revaluation amid growing concerns over escalating wildfires.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as anticipation builds for a Bankable Feasibility Study (BFS) update, widely believed to significantly enhance the valuation of its Greenland rare earth project. Community discussion highlights a potential short squeeze and the company's strategic importance in securing critical mineral supply chains amidst ongoing geopolitical realignments.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health (HIMS) is trending strongly after Novo Nordisk dropped its lawsuit and partnered to distribute branded GLP-1s, a move validating HIMS's telehealth platform and igniting significant short-squeeze speculation within the community. Analysts are rapidly upgrading price targets, with many investors believing the company is fundamentally undervalued and set for substantial long-term growth.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Its co-founders' departure to launch a new mRNA innovation company, a weak financial outlook, and reports of Pfizer selling part of its stake are driving BioNTech's conversation. This has sparked diverse community perspectives, ranging from concerns about the mRNA sector's future to speculation about a potential acquisition or a renewed focus on BNTX's promising oncology pipeline.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense & National Security, Space Solutions, and Starlab Space Stations. The Defense & National Security segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Space Solutions segment consists of space infrastructure, advanced space technology, science systems and mission services. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyager Technologies is experiencing mixed reactions following its latest Q4 earnings, which revealed a revenue miss but also a record backlog and increased FY26 guidance. The community is sharply divided, with bulls highlighting the potential of an imminent NASA Starlab Phase 2 award and growing defense contracts to drive significant upside, while skeptics point to past dilution concerns and recent volatile price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AZN $DSNKY  
 
AstraZeneca says Enhertu combo showed PFS improvement over THP in trial 
 
Results from the DESTINY-Breast09 Phase III trial showed Enhertu plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival compared to a taxane, trastuzumab and pertuzumab as a first-line treatment for patients with HER2-positive metastatic breast cancer, AstraZeneca announced. Results will be presented today during a special late-breaking oral session at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, the company noted.  
 
In a prespecified interim analysis, Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP. Median PFS was 40.7 months with Enhertu plus pertuzumab compared to 26.9 months for THP, as assessed by blinded independent central review. The PFS benefit for Enhertu plus pertuzumab versus THP was consistent across subgroups, including for the prespecified stratification factors of de novo or recurrent disease, hormone receptor status and PIK3CA mutation status.  
 
Investigator-assessed PFS demonstrated a median PFS of 40.7 months for Enhertu plus pertuzumab compared to 20.7 months for THP, the company noted. Overall survival was not mature at the time of the interim analysis; however, interim OS data showed an early trend favouring the Enhertu combination compared to THP, the company added. Susan Galbraith, Executive Vice President, Oncology Haematology R&amp;D, AstraZeneca (AZN), said: &quot;Bringing Enhertu earlier in the treatment of HER2-positive metastatic breast cancer may represent an important advancement for patients.  
 
The DESTINY-Breast09 trial showed the combination of Enhertu and pertuzumab in the first-line setting substantially increased the amount of time before a patient&#39;s cancer progressed compared to standard of care and nearly doubled the number of patients showing no signs of disease on imaging. Establishing a strong therapeutic response as soon as metastatic disease is diagnosed is critical given that about one in three patients do not receive further treatment after progressing in the first-line setting.&quot;  
 
Ken Takeshita, Global Head, R&amp;D, Daiichi Sankyo (DSNKY), said: &quot;Enhertu continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved outcomes for a broad population of patients with HER2-positive disease compared to THP in the first-line setting. DESTINY-Breast09 shows that initiating treatment with Enhertu in combination with pertuzumab at the time of metastatic diagnosis can delay disease progression.&quot;

Jake Harrison

Chipwars

Miguel

StockTwits Web

AstraZeneca PLC

Daiichi Sankyo Company

  
 
AstraZeneca says Enhertu combo showed PFS improvement over THP in trial 
 
Results from the DESTINY-Breast09 Phase III trial showed Enhertu plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival compared to a taxane, trastuzumab and pertuzumab as a first-line treatment for patients with HER2-positive metastatic breast cancer, AstraZeneca announced. Results will be presented today during a special late-breaking oral session at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, the company noted.  
 
In a prespecified interim analysis, Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP. Median PFS was 40.7 months with Enhertu plus pertuzumab compared to 26.9 months for THP, as assessed by blinded independent central review. The PFS benefit for Enhertu plus pertuzumab versus THP was consistent across subgroups, including for the prespecified stratification factors of de novo or recurrent disease, hormone receptor status and PIK3CA mutation status.  
 
Investigator-assessed PFS demonstrated a median PFS of 40.7 months for Enhertu plus pertuzumab compared to 20.7 months for THP, the company noted. Overall survival was not mature at the time of the interim analysis; however, interim OS data showed an early trend favouring the Enhertu combination compared to THP, the company added. Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca (AZN), said: "Bringing Enhertu earlier in the treatment of HER2-positive metastatic breast cancer may represent an important advancement for patients.  
 
The DESTINY-Breast09 trial showed the combination of Enhertu and pertuzumab in the first-line setting substantially increased the amount of time before a patient's cancer progressed compared to standard of care and nearly doubled the number of patients showing no signs of disease on imaging. Establishing a strong therapeutic response as soon as metastatic disease is diagnosed is critical given that about one in three patients do not receive further treatment after progressing in the first-line setting."  
 
Ken Takeshita, Global Head, R&D, Daiichi Sankyo (DSNKY), said: "Enhertu continues to transform the treatment of metastatic breast cancer with the first new data in more than a decade to demonstrate improved outcomes for a broad population of patients with HER2-positive disease compared to THP in the first-line setting. DESTINY-Breast09 shows that initiating treatment with Enhertu in combination with pertuzumab at the time of metastatic diagnosis can delay disease progression."